Clinical Oncology
Volume 21, Issue 4 , Pages 343-360 , May 2009

Escalation and Intensification of Radiotherapy for Stage III Non-small Cell Lung Cancer: Opportunities for Treatment Improvement

  • J.D. Fenwick

      Affiliations

    • Department of Medical Physics, Clatterbridge Centre for Oncology, Clatterbridge Road, Wirral CH63 4JY, UK
    • School of Cancer Studies, Liverpool University, Royal Liverpool University Hospital, Daulby Street, Liverpool L69 3GA, UK
    • Corresponding Author InformationAuthor for correspondence: J. D. Fenwick, Department of Medical Physics, Clatterbridge Centre for Oncology, Clatterbridge Road, Wirral CH63 4JY, UK. Tel: +44-151-334-1155 ext5272; Fax: +44-151-482-7860.
    • ,
  • A.E. Nahum

      Affiliations

    • Department of Medical Physics, Clatterbridge Centre for Oncology, Clatterbridge Road, Wirral CH63 4JY, UK
    • ,
  • Z.I. Malik

      Affiliations

    • Department of Clinical Oncology, Clatterbridge Centre for Oncology, Clatterbridge Road, Wirral CH63 4JY, UK
    • ,
  • C.V. Eswar

      Affiliations

    • Department of Clinical Oncology, Clatterbridge Centre for Oncology, Clatterbridge Road, Wirral CH63 4JY, UK
    • ,
  • M.Q. Hatton

      Affiliations

    • Department of Clinical Oncology, Weston Park Hospital, Witham Road, Sheffield S10 2SJ, UK
    • ,
  • V.M. Laurence

      Affiliations

    • Department of Clinical Oncology, Poole Hospital NHS Trust, Longfleet Road, Poole, Dorset BH15 2JB, UK
    • ,
  • J.F. Lester

      Affiliations

    • Department of Clinical Oncology, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK
    • ,
  • D.B. Landau

      Affiliations

    • Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, London SE1 7UH, UK

Received 7 October 2008 ,Revised 29 December 2008 ,Accepted 30 December 2008.

References 

  1. Saunders MI, Dische S, Barett A, et al. Continuous hyper-fractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet. 1997;350:161–165
  2. Maher EJ, Coia L, Duncan G, et al. Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys. 1992;23:239–244
  3. Maher EJ, Timothy A, Squire CJ, et al. Audit: the use of radiotherapy for NSCLC in the UK. Clin Oncol. 1993;5:72–79
  4. Webb S. The physics of three-dimensional radiation therapy. Bristol: IOP; 1993;
  5. Fenwick JD. Advances in intensity-modulated radiotherapy delivery. In:  Bentzen SM,  Harari PM,  Tomé W,  Mehta MP editor. Radiation oncology advances. New York: Springer; 2008;
  6. Jaffray DA. Image-guided radiation therapy: from concept to practice. Semin Radiat Oncol. 2007;17:243–244
  7. van Herk M. Different styles of image-guided radiotherapy. Semin Radiat Oncol. 2007;17:258–267
  8. Liengswangwong V, Bonner JA. Point: the potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer. Semin Radiat Oncol. 2000;10:308–314
  9. Williams TE, Thomas CR, Turrisi AT. Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol. 2000;10:315–323
  10. Senan S, Burger S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrence in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:999–1006
  11. Giraud P, de Rycke Y, Lavole A, et al. Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional radiotherapy?. Int J Radiat Oncol Biol Phys. 2006;64:127–135
  12. Belderbos JSA, Uitterhoeve A, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer. 2007;43:114–121
  13. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose-escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49:23–33
  14. Maguire PD, Marks LB, Sibley GS, et al. 73.6Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol. 2001;19:705–711
  15. Saunders MI, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (Continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol. 2002;14:352–360
  16. Wu K-L, Jiang G-L, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys. 2003;57:1336–1344
  17. Holloway CL, Robinson D, Murray B, et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small-cell lung cancer. Radiother Oncol. 2004;73:285–287
  18. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional radiation therapy. Radiother Oncol. 2004;71:163–166
  19. Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;3:741–747
  20. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127
  21. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  22. Belderbos JSA, Heemsbergen WD, de Jaeger K, et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  23. Kong F-M, Hayman JA, Griffith KA, et al. Final toxicity results of a dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictions for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006;65:1075–1086
  24. Schild SE, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1106–1111
  25. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  26. Krol AD, Aussems P, Noordijk EM, et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys. 1996;34:297–302
  27. Hayakawa K, Mitsuhashi N, Saito Y, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  28. Cheung PCF, Mackillop WJ, Dixon P, et al. Involved-field radiotherapy alone for early stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:703–710
  29. Chen M, Hayman JA, Ten Haken RK, et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys. 2006;64:120–126
  30. Christian JA, Bedford JL, Webb S, et al. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:735–741
  31. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–890
  32. Scrimger RA, Tomé WA, Olivera GH, et al. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol. 2003;26:70–78
  33. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258–1267
  34. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–1279
  35. Schwartz M, Alber M, Lebesque JV, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:561–570
  36. Chapet O, Thomas E, Kessler ML, et al. Esophagus sparing with IMRT in lung tumor irradiation: an EUD-based optimisation technique. Int J Radiat Oncol Biol Phys. 2005;63:179–187
  37. Chapet O, Khodri M, Jalade P, et al. Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol. 2006;80:333–340
  38. Bortfeld T, Jokivarsi K, Kung J, et al. Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol. 2002;47:2203–2220
  39. Jiang SB, Pope C, Al Jarrah KM, et al. An experimental investigation on intra-fractional organ motion effects in lung IMRT treatments. Phys Med Biol. 2003;48:1773–1784
  40. Duan J, Shen S, Fiveash JB, et al. Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: a volumetric dose measurement study. Med Phys. 2006;33:1380–1387
  41. Belderbos JSA, de Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003;66:119–126
  42. Ball D, Bishop J, Smith J, et al. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys. 1995;31:267–272
  43. King SC, Acker JC, Kussin PS, et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost treatment of nonsmall cell lung cancer: unusual toxicity and promising results. Int J Radiat Oncol Biol Phys. 1996;36:593–596
  44. Kwa SLS, Lebesque JV, Theuws JCM, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  45. Seppenwoolde Y, Muller SH, Theuws JCM, et al. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:681–690
  46. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2003;55:724–735
  47. de Jaeger K, Hoogeman MS, Engelsman M, et al. Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. Radiother Oncol. 2003;69:1–10
  48. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys. 2002;54:329–339
  49. Yorke ED, Jackson A, Rosenzweig KE, et al. Correlations of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:672–682
  50. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66:1399–1407
  51. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650–659
  52. Miller KL, Shapman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?. Int J Radiat Oncol Biol Phys. 2005;61:64–69
  53. Schultheiss TE, Orton CG, Peck RA. Models in radiotherapy: volume effects. Med Phys. 1983;10:410–415
  54. Lebesque JV, Keus RB. The simultaneous boost technique: the concept of relative normalised total dose. Radiother Oncol. 1991;22:45–55
  55. Bentzen SM, Baumann M. The linear-quadratic model in clinical practice. In:  Steel GG editors. Basic clinical radiobiology. 3rd edn. London: Arnold; 2002;
  56. Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002;52:1041–1046
  57. Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastasis. Semin Radiat Oncol. 2006;16:77–84
  58. Sampson MC, Katz A, Constine LS. Stereotactic body radiation therapy for extracranial oligometastasis: does the sword have a double edge?. Semin Radiat Oncol. 2006;16:67–76
  59. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumours in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  60. Hof H, Hoess A, Oezel D, et al. Stereotactic single-dose radiotherapy of lung metastasis. Strahlenther Onkol. 2007;183:673–678
  61. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  62. Marks LB, Munley MT, Bentel GC, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 1997;39:563–570
  63. Dawson LA, Biersack M, Lockwood G, et al. Use of principal components analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys. 2005;62:829–837
  64. Yorke ED, Kutcher GJ, Jackson A, Ling CC. Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation. Radiother Oncol. 1993;26:226–237
  65. Theuws JC, Kwa SL, Wagenaar AC, et al. Dose–effect relations for early local pulmonary injury after irradiation for malignant lymphoma and breast cancer. Radiother Oncol. 1998;48:3–43
  66. van Dyk J, Mak K, Keane TJ. Radiation-induced lung damage: dose-time-fractionation considerations. Radiother Oncol. 1989;14:55–69
  67. Bentzen SM, Skoczylas JZ, Bernier J. Quantitative clinical radiobiology of early and late lung reactions. Int J Radiat Biol. 2000;76:453–462
  68. Seppenwoolde Y, de Jaeger K, Boersma LJ, et al. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:748–758
  69. Bentzen SM, Saunders MI, Dische S. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome. Clin Oncol. 2002;14:372–381
  70. Boersma LJ, Damen EMF, de Boer RW, et al. Dose–effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma. Radiother Oncol. 1994;32:201–209
  71. Rosen , Fischer TA, Antolak JA, et al. Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer. Radiology. 2001;221:614–622
  72. Thames HD. An ‘incomplete-repair’ model for survival after fractionated and continuous irradiations. Int J Radiat Biol. 1985;47:319–339
  73. van Rongen E, Madhuizen HT, Tan CHT, et al. Early and late effects of fractionated irradiation and the kinetics of repair in rat lung. Radiother Oncol. 1990;17:323–337
  74. AAPM Task Group 64 . AAPM Report 85: tissue inhomogeneity corrections for megavoltage photon beams. Madison: Medical Physics Publishing; 2004;
  75. Choy H, LaPorte H, Knill-Selby E, et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 1999;9:90–96
  76. Werner-Wasik M. Treatment-related esophagitis. Semin Oncol. 2005;32:S60–S66
  77. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre study. Radiother Oncol. 1999;52:137–148
  78. Byhardt RW, Pajak TF, Emami B, et al. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys. 1993;26:459–468
  79. Mehta MP, Tannehill SP, Adak S, et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol. 1998;16:3518–3523
  80. Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129–136
  81. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol. 2003;69:161–168
  82. Bentzen SM, Ruifrok ACC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol. 1996;38:89–101
  83. Dörr W, Hamilton CS, Boyd T, et al. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys. 2002;52:911–917
  84. Fenwick JD, Lawrence GP, Malik Z, et al. Early mucosal reactions during and following head and neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule duration. Int J Radiat Oncol Biol Phys. 2008;71:625–634
  85. Maguire PD, Sibley GS, Zhou S-M, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999;45:97–103
  86. Werner-Wasik M, Pequignot E, Leeper D, et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys. 2000;48:689–696
  87. Hirota S, Tsujino K, Masahiro E, et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51:291–295
  88. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:337–341
  89. Patel AB, Edelman MJ, Young K, et al. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60:1106–1112
  90. Kahn DK, Zhou S, Ahn S-J, et al. ‘Anatomically-correct’ dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics. Int J Radiat Oncol Biol Phys. 2005;62:645–651
  91. Kim TH, Cho KH, Hong RP, et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:995–1002
  92. Takeda K, Nemoto K, Saito H, et al. Dosimetric correlates of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:626–629
  93. Belderbos J, Heemsbergen W, Hoogeman M, et al. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol. 2005;75:157–164
  94. El-Naqa I, Bradley J, Blanco AI, et al. Multivariate modelling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys. 2006;64:1275–1286
  95. Wei X, Liu HH, Tucker SL, et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:100–107
  96. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  97. Fowler JF, Bentzen SM, Bond SJ, et al. Clinical radiation doses for spinal cord: the 1998 international questionnaire. Radiother Oncol. 2000;55:295–300
  98. van der Kogel AJ. The nervous system: radiobiology and experimental pathology. In:  Scherer E,  Streffer C,  Trott K-R editor. Radiopathology of organs and tissues. Berlin: Springer; 1991;
  99. Ang KK, Jiang GL, Guttenberger R, et al. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol. 1992;25:287–294
  100. Schultz-Hector S, Sund M, Thames HD. Fractionation response and repair kinetics of radiation induced heart failure in the rat. Radiother Oncol. 1992;23:33–40
  101. McChesney Gillette S, Gillette EL, Shida T, et al. Late radiation response of canine mediastinal tissues. Radiother Oncol. 1992;23:41–52
  102. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–37
  103. Fenwick JD. Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression. Phys Med Biol. 1998;43:2159–2178
  104. Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys. 2004;59:242–249
  105. Fowler JF. Optimum overall times II: extended modelling for head and neck radiotherapy. Clin Oncol. 2008;20:113–126
  106. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionation or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854
  107. Ardizzoni A, Scolaro T, Mereu C, et al. Induction chemotherapy with carboplatin–paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer. Am J Clin Oncol. 2005;28:58–64
  108. Yokoyama A, Kurita Y, Saijo N, et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer. 1998;78:257–262
  109. Tsuchiya S, Ohe Y, Sugiura T, et al. Randomized phase 1 study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of the Japan Clinical Oncology Group Study (JCOG 9601). Jpn J Clin Oncol. 2001;31:488–494
  110. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  111. Curran WJ, Scott CB, Langer CC, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621
  112. Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer. Cancer Sci. 2001;95:691–695
  113. Zatloukal PV, Petruzelka L, Zemanova M, et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol. 2002;21:290a
  114. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. (Review) Cochrane Database Syst Rev. 2004;CD002140
  115. Seppenwoolde Y, de Jaeger K, Lebesque JV. In regard to Tsujino et al.: predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoirradiation for lung cancer. IJROBP 2003;55:110–115 Int J Radiat Oncol Biol Phys. 2003;56:1208–1209
  116. Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. Cancer Sci. 2006;95:691–695
  117. Semrau S, Bier A, Thirbach U, et al. 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol. 2007;192:30–35
  118. Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol. 2002;20:191–198
  119. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique – Groupe Français de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol. 2005;23:5910–5917
  120. Kim DW, Shyr Y, Shaktour B, et al. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 2005;50:235–245
  121. Vergnenègre A, Daniel C, Léna H, et al. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie. Lung Cancer. 2005;47:395–404
  122. van Baardwijk A, Bosmans G, Bentzen SM, et al. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys. 2008;71:1103–1110
  123. Wara WM, Philips TL, Margolis LW, Smith V. Radiation pneumonitis: a new approach to the derivation of time-dose factors. Cancer. 1973;32:547–552
  124. Okunieff P, Morgan D, Niemierko A, Suit HD. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys. 1995;32:1227–1237
  125. Buffa FM, Bentzen SM, Daley FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res. 2004;10:3745–3754

PII: S0936-6555(09)00030-2

doi: 10.1016/j.clon.2008.12.011

Clinical Oncology
Volume 21, Issue 4 , Pages 343-360 , May 2009

Article Tools

* Image Usage & Resolution